Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells.
OBJECTIVE
No study has evaluated the antiproliferative effects of thiazolidinediones and antiblastics in 'primary cultured human anaplastic thyroid cancer cells'.


METHODS
Primary anaplastic cells proliferation was evaluated after incubation with increasing concentrations of rosiglitazone or pioglitazone or antiblastics (bleomycin, cisplatin, gemcitabine) by a proliferation assay (WST-1-tetrazolium reaction) and cell counting.


RESULTS
A reduction of proliferation by thiazolidinediones at 1 h (from the start of tetrazolium reaction) [of 11% and 25%, with rosiglitazone, 10 or 20 (P = 0.0001) microM, respectively; of 7% and 17%, with pioglitazone, 10 or 20 (P = 0.0125) microM, respectively], and at 2 h [of 14% and 24%, with rosiglitazone, 10 (P = 0.0043) or 20 (P < 0.0001) microM, respectively; of 9% and 21%, with pioglitazone, 10 (P = 0.0397) or 20 (P = 0.0001) microM, respectively] was shown. No significant thiazolidinediones effect was observed in normal thyroid follicular cells. Bleomycin, cisplatin and gemcitabine significantly (P < 0.0001) inhibited (> 50%) anaplastic cells proliferation. Cell counting confirmed the above mentioned results. Inhibition of proliferation was similar in tumours with or without (V600E)BRAF mutation, both for thiazolidinediones and antiblastics.


CONCLUSIONS
Thiazolidinediones exert an antiproliferative effect in primary cultured human anaplastic carcinoma cells in vitro, such as antiblastics.
Antonelli
Alessandro
A
Department of Internal Medicine, University of Pisa, via Roma, 67, I-56100, Pisa, Italy. a.antonelli@med.unipi.it
Ferrari
Silvia Martina
SM
Fallahi
Poupak
P
Berti
Piero
P
Materazzi
Gabriele
G
Minuto
Michele
M
Giannini
Riccardo
R
Marchetti
Ivo
I
Barani
Lucio
L
Basolo
Fulvio
F
Ferrannini
Ele
E
Miccoli
Paolo
P
D002277:Carcinoma / Q000188:drug therapy* / Q000503:physiopathology; D049109:Cell Proliferation / Q000187:drug effects*; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D014407:Tumor Cells, Cultured
D006131:Growth Inhibitors; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone